TMS Co., Ltd.

Equities

4891

JP3544960002

Biotechnology & Medical Research

Market Closed - Japan Exchange 07:00:00 24/06/2024 BST 5-day change 1st Jan Change
237 JPY +1.28% Intraday chart for TMS Co., Ltd. +11.79% +26.06%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
TMS Co., Ltd. Announces Dosing to the First Subject in TMS-008 Phase I Clinical Trial CI
Equinor: contract with Vallourec in Brazil CF
Equinor: contract with Vallourec in Brazil CF
Tennant Minerals Produces 'High-Grade' Concentrates from Bluebird Discovery Samples MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Jefferies Adjusts TMS’ Price Target to 760 Yen From 730 Yen, Keeps at Buy MT
Tennant Minerals Raises AU$4.8 Million for Drilling, Target Testing; Shares Down 4% MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
Tennant Minerals Finds 23% Copper Concentrate, 1.5G/T Gold at Bluebird Project MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise MT
Tennant Minerals to Commence Next Phase of Drilling at Barkly Project; Shares Down 3% MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
TMS Co., Ltd. Submits Clinical Trial Plan Notification for TMS-008 Phase I Clinical Trial in Japan CI
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Greenbrook TMS Shares Tumble Ahead of Delisting; Trading to be Suspended Monday MT
Chart TMS Co., Ltd.
More charts
TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
234 JPY
Average target price
760 JPY
Spread / Average Target
+224.79%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 4891 Stock
  4. News TMS Co., Ltd.
  5. Jefferies Adjusts TMS Co’s Price Target to 730 Yen From 780 Yen, Keeps at Buy